Sentiment-Signal
22,4
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
80.9
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 07.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 11.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 09.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 26.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appo |
| 30.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Unternehmen & Branche
| Name | ACHIEVE LIFE SCIENCES, INC. |
|---|---|
| Ticker | ACHV |
| CIK | 0000949858 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 221,9 Mio. USD |
| Beta | 1,96 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -54,648,000 | -1.25 | 41,790,000 | 21,518,000 | |
| 2025-09-30 | 10-Q | -14,441,000 | -0.28 | 52,040,000 | 33,615,000 | |
| 2025-06-30 | 10-Q | -12,718,000 | -0.37 | 58,935,000 | 41,668,000 | |
| 2025-03-31 | 10-Q | -12,827,000 | -0.37 | 27,358,000 | 10,279,000 | |
| 2024-12-31 | 10-K | -39,827,000 | -1.24 | 38,633,000 | 20,899,000 | |
| 2024-09-30 | 10-Q | -12,512,000 | -0.36 | 47,917,000 | 31,378,000 | |
| 2024-06-30 | 10-Q | -8,461,000 | -0.25 | 64,791,000 | 42,285,000 | |
| 2024-03-31 | 10-Q | -6,494,000 | -0.26 | 70,029,000 | 49,456,000 | |
| 2023-12-31 | 10-K | -29,815,000 | -1.50 | 19,371,000 | -1,448,000 | |
| 2023-09-30 | 10-Q | -7,108,000 | -0.34 | 24,337,000 | 4,038,000 | |
| 2023-06-30 | 10-Q | -8,239,000 | -0.43 | 28,915,000 | 9,699,000 | |
| 2023-03-31 | 10-Q | -8,992,000 | -0.50 | 20,798,000 | 443,000 | |
| 2022-12-31 | 10-K | -42,350,000 | -4.00 | 29,971,000 | 8,303,000 | |
| 2022-09-30 | 10-Q | -13,077,000 | -1.35 | 23,723,000 | 1,044,000 | |
| 2022-06-30 | 10-Q | -10,468,000 | -1.08 | 33,985,000 | 13,166,000 | |
| 2022-03-31 | 10-Q | -7,573,000 | -0.80 | 40,614,000 | 21,433,000 | |
| 2021-12-31 | 10-K | -7,151,000 | -4.08 | 47,516,000 | 28,042,000 | |
| 2021-09-30 | 10-Q | -6,691,000 | -0.71 | 37,799,000 | 34,700,000 | |
| 2021-09-30 | 10-K | -6,691,000 | ||||
| 2021-06-30 | 10-K | -11,311,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-18 | Stewart Richard Alistair | Director, Officer, Chief Executive Officer | Open Market Sale | -129,501 | 2.92 | -378,142.92 | -209,1% | |
| 2025-09-18 | Oki Mark K | Officer, Chief Financial Officer | Open Market Sale | -50,060 | 2.92 | -146,175.20 | -80,8% | |
| 2025-09-04 | KING THOMAS BRAXTON | Director | Open Market Sale | -139,858 | 2.77 | -387,406.66 | -214,2% | |
| 2025-09-04 | Xinos Jaime | Officer, Chief Commercial Officer | Open Market Sale | -20,854 | 2.77 | -57,765.58 | -31,9% | |
| 2025-09-04 | Wan Jerry | Officer, Principal Accounting Officer | Open Market Sale | -14,070 | 2.77 | -38,973.90 | -21,6% | |
| 2025-09-04 | JACOBS CINDY | Officer, President & CMO | Open Market Sale | -27,629 | 2.77 | -76,532.33 | -42,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.